| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
Acell targets adenosine receptors as an antagonist. Adenosine receptors are G protein-coupled receptors that mediate the effects of adenosine, a nucleoside involved in various physiological processes. By acting as an adenosine receptor antagonist, Acell modulates adenosine signaling. The compound is also a synthetic cytokinin analogue that promotes chlorophyll retention and delays senescence in plant tissues. Its activity as a growth regulator has been characterized in plant models.
|
|---|---|
| ln Vitro |
These procedures heavily rely on the cytokinin derivative BAP9THP, which when cultured on conditions containing it produces notable shoot proliferation [1] when applied to isolated apical meristems or growing shoot tips. According to studies, BAP9THF and BAP9THP are both more effective than BAP at delaying aging and eliciting different growth responses [2].
In vitro, Acell has been shown to promote chlorophyll retention and delay senescence in plant tissues. It promotes chlorophyll retention unusually strongly, while tobacco callus growth is almost as strong as that of 6-benzylaminopurine (BAP). These effects are consistent with its role as a cytokinin analogue. Acell's activity as an adenosine receptor antagonist has also been characterized. |
| ln Vivo |
In vivo data for Acell are primarily from plant studies. The compound promotes chlorophyll retention and delays senescence in plant tissues. It has been shown to promote tobacco callus growth almost as strongly as BAP. These effects demonstrate Acell's activity as a cytokinin analogue and growth regulator in plant models.
|
| Enzyme Assay |
In non-cell-based biochemical assays, Acell's activity as an adenosine receptor antagonist is evaluated using radioligand competition binding experiments. Membrane preparations from cells expressing adenosine receptors are incubated with a radiolabeled adenosine receptor ligand and varying concentrations of Acell. After incubation, bound and free radioligand are separated, and radioactivity is measured. Competition curves are generated to determine IC50 and Ki values, confirming the compound's adenosine receptor antagonist activity.
|
| Cell Assay |
In vitro cellular assays for Acell involve testing its effects on plant cells and tissues. The compound's ability to promote chlorophyll retention and delay senescence is assessed in plant tissue culture models. Its effects on callus growth are measured in tobacco callus assays. These assays confirm Acell's activity as a cytokinin analogue and growth regulator.
|
| Animal Protocol |
In vivo animal studies for Acell are not applicable as the compound is primarily studied as a plant growth regulator and adenosine receptor antagonist. The compound is not intended for use in animals or humans. Its effects have been characterized primarily in plant models.
|
| ADME/Pharmacokinetics |
Detailed pharmacokinetic properties of Acell are not applicable as the compound is primarily a research chemical used in plant studies and biochemical assays. The compound has a molecular weight of 309.37. Storage conditions and solubility data are not extensively reported in publicly available sources.
|
| Toxicity/Toxicokinetics |
Toxicological data for Acell are limited in publicly available sources. As a research compound intended for laboratory use, comprehensive toxicology studies have not been extensively published. The compound is not intended for human use and should be handled with appropriate safety precautions. Its safety profile is consistent with that of other research chemicals used in laboratory settings.
|
| References |
[1]. Smýkalová, I., et al. The effects of novel synthetic cytokinin derivatives and endogenous cytokinins on the in vitro growth responses of hemp (Cannabis sativa L.) explants. Plant Cell Tiss Organ Cult 139, 381–394 (2019).
[2]. Vylíčilová H, et al. Naturally Occurring and Artificial N9-Cytokinin Conjugates: From Synthesis to Biological Activity and Back. Biomolecules. 2020;10(6):832. Published 2020 May 29. |
| Additional Infomation |
Acell (BAP9THP, N-benzyl-9-(tetrahydro-2H-pyran-2-yl)adenine) is a synthetic cytokinin analogue and growth regulator. It belongs to the class of adenosine receptor antagonists and promotes chlorophyll retention and delays senescence in plant tissues. Acell promotes tobacco callus growth almost as strongly as BAP. It is a bioactive chemical used in research applications and is not an approved drug.
|
| Molecular Formula |
C17H19N5O
|
|---|---|
| Molecular Weight |
309.36566
|
| Exact Mass |
309.158
|
| CAS # |
2312-73-4
|
| PubChem CID |
16834
|
| Appearance |
White to off-white solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
541.1±60.0 °C at 760 mmHg
|
| Melting Point |
110-114ºC
|
| Flash Point |
281.1±32.9 °C
|
| Vapour Pressure |
0.0±1.4 mmHg at 25°C
|
| Index of Refraction |
1.700
|
| LogP |
2.45
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
23
|
| Complexity |
376
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
N1(C2CCCCO2)C=NC3=C(NCC4=CC=CC=C4)N=CN=C13
|
| InChi Key |
POFWRMVFWIJXHP-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C17H19N5O/c1-2-6-13(7-3-1)10-18-16-15-17(20-11-19-16)22(12-21-15)14-8-4-5-9-23-14/h1-3,6-7,11-12,14H,4-5,8-10H2,(H,18,19,20)
|
| Chemical Name |
N-benzyl-9-(oxan-2-yl)purin-6-amine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.2324 mL | 16.1619 mL | 32.3238 mL | |
| 5 mM | 0.6465 mL | 3.2324 mL | 6.4648 mL | |
| 10 mM | 0.3232 mL | 1.6162 mL | 3.2324 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT00352729 | Withdrawn | Device: ACell dressing | Burns | United States Army Institute of Surgical Research |
November 2006 | Not Applicable |
| NCT01970306 | Completed Has Results | Device: MatriStem PSM | Esophageal Adenocarcinoma | Memorial Sloan Kettering Cancer Center |
October 18, 2013 | Phase 2 |
| NCT04041037 | Terminated Has Results | Device: Wound Sheet Matrix 2-Layer and Powder Urinary Bladder Matrix |
Pilonidal Disease | Integra LifeSciences Corporation | March 26, 2019 | |
| NCT03058731 | Completed | Device: Matristem Device: Control |
Paraesophageal Hernia | University of South Florida | February 2, 2016 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
